Results 31 to 40 of about 14,471,607 (152)

Integrated Predictors by Propensity Scoring With Tumor Markers and Plasma Levels of microRNA-21-5p, IL-17, and IL-10 Complement Early Detection of Hepatocellular Carcinoma in Patients With Liver Cirrhosis

Technology in Cancer Research & Treatment, 2023
Objectives: The clinical usefulness of tumor markers alpha-fetoprotein (AFP) and des-gamma carboxyprothrombin (DCP) in the early detection of hepatocellular carcinoma (HCC) in patients with liver cirrhosis (LC), including those with marker decline after ...
Maiko Machida PhD, Mayuko Ambo, Runa Mishina, Nanaka Hada, Fuhito Tachibana, Miki Yamashita PhD, Ainari Konda PhD, Kunihiko Tsuji MD, PhD   +7 more
doaj   +1 more source

Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection.

PLoS ONE, 2019
Background/aimsIt is important to identify patients who are refractory to transarterial chemoembolization (TACE), which is performed for the treatment of hepatocellular carcinoma (HCC).
Mi Young Jeon, Hye Soo Kim, Tae Seop Lim, Dai Hoon Han, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Gi Hong Choi, Jin Sub Choi, Kwang-Hyub Han, Seung Up Kim   +11 more
doaj   +1 more source

DCP as a biomarker for TACE efficacy in hepatocellular carcinoma

Frontiers in Oncology
IntroductionPrimary hepatocellular carcinoma (PHC) requires advanced diagnostic and therapeutic strategies. While transcatheter arterial chemoembolization (TACE) is a cornerstone treatment, efficacy assessment remains challenging.MethodsWe ...
Hui Xie, Youwei Li, Jie Yang, Yuwei Tan, Jin Xu, Xiao Yang   +5 more
doaj   +1 more source

Serum Biomarkers For Hepatocellular Carcinoma (Short Review)

Indonesian Journal of Cancer, 2009
Hepatocellular carcinoma (HCC) atau kanker hati adalah salah satu dari kanker yang paling umum dan menjadi penyebab utama kematian di negara-negara Asia. HCC biasanya berkembang pada pasien dengan penyakit hati kronis dan sirosis.
Indra Bachtiar, Andi Utama, Susan Tai
doaj   +1 more source

The development of a novel native prothrombin assay for the more efficient management of oral anticoagulation therapy [PDF]

, 2004
Disturbances of the natural balance between pro-coagulant and anticoagulant systems, due to hereditary or acquired factors may result in haemorrhagic or thrombotic diseases.
Sylvester, Adrian Jose
core   +5 more sources

When Explant Surprises: Management and Outcomes of Hepatocellular Carcinoma Beyond Milan Criteria Discovered Post‐Transplant‐ A Narrative Review of Literature

Journal of Surgical Oncology, EarlyView.
ABSTRACT Liver transplantation (LT) is the definitive treatment for early hepatocellular carcinoma (HCC), based on established criteria. Pre‐transplant imaging occasionally underestimates the tumor burden or biological aggressiveness, leading to explant pathology that exceeds the projection criteria, such as Milan.
Serkan Sucu, Brian Longbottom, Hassan Aziz   +2 more
wiley   +1 more source

Rapid Intrasegmental Progression After Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma: Incidence, Imaging Features, and Clinical Outcomes

Hepatology Research, EarlyView.
ABSTRACT Aim Radiofrequency ablation (RFA) is curative therapy for early‐stage hepatocellular carcinoma (HCC), but a rare subset of patients develop aggressive intrasegmental recurrence shortly after complete ablation. We characterized the incidence, risk factors, and absolute risk.
Takuma Kaneko, Takuma Nakatsuka, Ryosuke Tateishi, Keisuke Mabuchi, Yuki Matsushita, Tomoharu Yamada, Tatsuya Minami, Masaya Sato, Mitsuhiro Fujishiro   +8 more
wiley   +1 more source

Atezolizumab Plus Bevacizumab Treatment for Patients With Hepatocellular Carcinoma in the Barcelona Clinic Liver Cancer B2 Stage

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim The optimal treatment strategy for patients with intermediate‐stage hepatocellular carcinoma beyond the up‐to‐seven criteria (Barcelona Clinic Liver Cancer B2) remains uncertain. Although transarterial chemoembolization has long been the standard of care, its efficacy is limited in this subgroup, and systemic therapies have ...
Keishi Ouchi, Masashi Ninomiya, Mio Tsuruoka, Jun Inoue, Atsushi Hiraoka, Kosuke Sato, Kotaro Doi, Kengo Watanabe, Tomoya Sasazaki, Takayoshi Oikawa, Kei Endo, Tamami Abe, Masashi Fujita, Kazumichi Abe, Tomohiro Katsumi, Wataru Sato, Chikara Iino, Nobukazu Tanabe, Hiroshi Numao, Hiromasa Ohira, Hidekatsu Kuroda, Yoshiyuki Ueno, Atsushi Masamune   +22 more
wiley   +1 more source

Expert consensus on the role of hematological markers in the early clinical screening of hepatocellular carcinoma

Liver Research, 2022
The disease burden of hepatocellular carcinoma (HCC) in China is heavy, and the prognosis is still unfavourable. Therefore, early screening of high-risk groups of HCC through simple methods is the key to achieving early diagnosis and treatment and ...
doaj   +1 more source

A Novel Diagnostic Approach for Hepatocellular Carcinoma Using Glycosylated Ferritin

Hepatology Research, Volume 56, Issue 9, Page 1319-1330, September 2026.
The percentage of glycosylated ferritin relative to total ferritin (%GF) is a novel biomarker for hepatocellular carcinoma (HCC), showing diagnostic performance comparable to that of AFP and DCP. We developed the GFAD index by integrating age, sex, %GF, AFP, and DCP, achieving improved diagnostic accuracy with high sensitivity and specificity. ABSTRACT
Akiyo Ishiguro, Yutaka Suehiro, Issei Saeki, Maho Egusa, Norikazu Tanabe, Toshihiko Matsumoto, Tsuyoshi Ishikawa, Yuki Kunimune, Toshihiko Kobayashi, Mitsuaki Nishioka, Taro Takami, Takahiro Yamasaki   +11 more
wiley   +1 more source